



SeraGene Therapeutics Inc.

Vision

A world where no person at risk of bleeding or thrombosis is denied the protection they need.


Mission

To create next generation RNA therapies that provide long-lasting protection for all patients with bleeding disorders or at risk of thrombosis, including those ineligible for current therapies.

Core Technology

RNA agents that modulate the level of specific coagulation factors in blood to prevent and treat bleeding and thrombosis.

SeraGene's therapeutics modulate the amount of specific coagulation proteins in the blood.



SeraGene Therapeutics harnesses nanomedicine technologies to develop the next generation of hematological therapeutics.

SeraGene leverages an expansive network of thought leaders and hematology clinicians and researchers, and a library of intellectual property on RNA delivery.

Providing long-lasting therapies that protect patients from chronic bleeding and thrombosis—and the associated long-term effects—improves patient quality of life, and provides value to the medical system by saving the time of healthcare professionals and reducing each patient's health burden.

SeraGene Therapeutics Inc.

Vancouver, BC, Canada

a.stirilchuk@seragenetx.com

RNA THERAPIES >> TO TREAT BLEEDING DISORDERS & THROMBOSIS

SeraGene's RNA agents are targeted to correct coagulation disorders long-term.

Leadership



Erika Siren
CEO



Amy Strilchuk
Director, Partnerships



Lin Jiin Juang
Director, CSO



Christian Kastrup
Board Chair



Pieter Cullis
Director



Katherine Badior
Co-Founder